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Background: Schimke immuno-osseous dysplasia (SIOD, OMIM #242900) is an autosomal-recessive pleiotropic
disorder characterized by spondyloepiphyseal dysplasia, renal dysfunction and T-cell immunodeficiency. SIOD is
caused by mutations in the gene SMARCAL1.
Case presentation: We report the clinical and genetic diagnosis of a 5-years old girl with SIOD, referred to our
Center because of nephrotic-range proteinuria occasionally detected during the follow-up for congenital
hypothyroidism. Mutational analysis of SMARCAL1 gene was performed by polymerase chain reaction (PCR) and
bidirectional sequencing. Sequence analysis revealed that patient was compound heterozygous for two SMARCAL1
mutations: a novel missense change (p.Arg247Pro) and a well-known nonsense mutation (p.Glu848*).
Conclusion: This report provided the clinical and genetic description of a mild phenotype of Schimke immuno-osseous
dysplasia associated with nephrotic proteinuria, decreasing after combined therapy with ACE inhibitors and sartans. Our
experience highlighted the importance of detailed clinical evaluation, appropriate genetic counseling and molecular
testing, to provide timely treatment and more accurate prognosis.
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Schimke Immuno-Osseous Dysplasia [SIOD; OMIM #2
42900] is a rare autosomal recessive multisystem disorder,
firstly described in 1971 [1,2]. Approximately 50 cases
have been reported in the literature so far, without any ap-
parent sex, ethnic or geographic predilection. The exact
prevalence of the disease is unknown, in North America
the incidence is estimated at 1:1,000,000 to 1:3,000,000 live
births. Typical findings of SIOD are spondyloepiphyseal
dysplasia with disproportionate growth failure, typical fa-
cial appearance, nephrotic syndrome with focal segmental
glomerulosclerosis (FSGS) and progressive renal failure,
recurrent lymphopenia, T-cell immunodeficiency, and pig-
ment naevi [1-3]. Other features include hypothyroidism,
episodic cerebral ischaemia and bone marrow failure [4].* Correspondence: mariogiordanobari@fastwebnet.it
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article, unless otherwise stated.The SIOD phenotype may range from a severe variant with
in utero onset to a milder form with later onset [5,6]. SIOD
is caused by mutations in the gene encoding HepA-related
protein (HARP) also known as SMARCAL1 [SWI/SNF-re-
lated, matrix associated, actin-dependent regulator of chro-
matin, subfamily a-like 1; Gene ID: 50485; NG_009771.1], a
protein homologous to the sucrose non fermenting type 2
(SNF2) family of chromatin-remodeling proteins, required
for transcriptional regulation, replication, repair, recombin-
ation, and covalent modification [7-11]. Biallelic putative
loss of function mutations in SMARCAL1 gene are the
only identified causes of SIOD, however approximately half
of patients referred for molecular studies have no detectable
mutations in the coding region of this gene, thus environ-
mental, genetic, or epigenetic modifiers and the existence
of endophenotypes of SIOD have been hypothesized [10].
Here, we report the clinical and genetic diagnosis of a 5-
years old girl with SIOD, referred to our Center becausetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Renal histology of SIOD patient. Light microscopy
images (A, B) showing larger glomerular volume, with a sclerotic
lesion of the glomerular tuft. The remaining part of the glomerulus
shows focal and segmental matrix increase and mesangial
proliferation. Diffuse tubular atrophy and rare arteriolar ialinosis are
also present (A: PAS staining, B: Masson’s Trichrome stain; ×400).
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ing the follow-up for congenital hypothyroidism.
Case presentation
The patient was born at 29 week of gestation as the first
child of healthy non-consanguineous Italian parents.
Her birth weight was 720 g (<3rd percentile). Congenital
hypothyroidism was quickly diagnosed and substitutive
therapy was started at birth time. At 5-years, she was re-
ferred to our Pediatric Nephrology Center. At clinical
examination she had disproportionately short stature
(94 cm; <3rd percentile), low weight (13,5 kg; <3rd per-
centile), reduced occipitofrontal head circumference
(OFC) (48,1 cm; <3rd percentile), dorsolumbar kyphos-
coliosis, fine hair, pale skin, low nasal bridge. She had nor-
mal intelligence and never had severe infections, migraines
or transient ischemic attacks. Moreover she did not present
short neck or trunck, hyperpigmented macules, corneal
opacities or hypertension. Laboratory data showed neph-
rotic range proteinuria (1,7 g/die; 125 mg/kg/die) and nor-
mal renal function (creatinine clearance 84,75 ml/min,
according to the Schwartz-formula). Lymphopenia with T-
cell deficiency was also detected. Skeletal radiograph re-
vealed dorsolumbar kyphoscoliosis with unbalanced iliac
crests, but other findings consistent with the diagnosis of
spondyloepiphyseal dysplasia, such as ovoid and mildly flat-
tened vertebral bodies, small deformed capital femoral
epiphyses, and shallow dysplastic acetabular fossae, were
absent. The renal biopsy was performed and revealed FSGS
(Figure 1A-B). Treatment with ramipril and irbesartan re-
sulted in a reduction of proteinuria (0,104 g/die). After
two-years follow-up, the patient displays normal renal func-
tion without proteinuria and no episodes of infection or
cerebrovascular complication.
On the basis of clinical and laboratory findings, a diag-
nosis of SIOD was suspected. After obtaining informed
consent for genetic studies, genomic DNA was purified
from peripheral blood samples of proband and all available
family members (one sibling, mother and father) using
standard procedures.
Mutational analysis of SMARCAL1 gene [NM_014140.3
GI:187761312; NG_009771.1 GI:223671908; GeneID: 50
485] was performed by polymerase chain reaction (PCR)
and bidirectional sequencing of the coding exons and in-
tron/exon flanking regions, as previously described [12].
SMARCAL1 flanking intronic primers were designed
using primer3 program (http://primer3.wi.mit.edu/). PCR
products were sequenced using the Big Dye Terminator
v3.1 cycle sequencing kit on 3130 Genetic Analyzer (Life
Technologies, Ltd). SMARCAL1 mutation was named ac-
cording to Human Genome Variation Society recommen-
dations (www.hgvs.org/mutnomen) and NCBI Reference
Sequence [NM_014140.3 GI:187761312]. The potential ef-
fect of novel missense mutation was analyzed using SIFT(Sorting Intolerant From Tolerant) programme [13] and
Polyphen programme [14].
Sequence analysis revealed that patient was compound
heterozygous for two mutations (Figure 2A): a novel mis-
sense mutation in exon 3 (c.740G > C), resulting in an
arginine-to-proline substitution (p.Arg247Pro), inherited
by the mother; and a nonsense paternally-derived muta-
tion in exon 17 (c.2542G > T) resulting in the substitution
of Glu848 with a stop codon (p.Glu848*) [9]. The healthy
brother was wild type for detected mutations (data not
shown). This study have been performed in accordance
with the Declaration of Helsinki and was approved by the
Ethical Committee of University Hospital in Foggia.
Conclusions
SIOD is a rare autosomal recessive pleiotropic disorder
caused by mutations in SMARCAL1 gene [1,2]. So far,
about 55 different mutations in SMARCAL1 gene have
been identified in SIOD patients from different ethnic
backgrounds [9,10,15,16]. The pathogenesis of SIOD is
Figure 2 Genetic analysis. A. Electropherograms showing detected mutations of SMARCAL1 gene [NM_014140.3 GI:187761312] in exons 3 and
17 of proband and parents. B. Multi-sequence alignments by ClustalW software.
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related protein (HARP), a member of the SNF2 family of
ATPases, acting as chromatin remodelers within multi-
protein complexes [11]. This protein is an ATP-driven an-
nealing helicase, involved in a wide range of biological
functions, including transcription, DNA replication, and
DNA repair. SIOD patients exhibit a continuum from
mild to severe disease. Severe form is characterized by
intrauterine growth retardation, severe growth failure after
birth, recurrent infections, hematological abnormalities,hypothyroidism, cerebrovascular disease and often death
within the first 15-years. Mild form usually displays growth
failure and renal dysfunction between 8–12 years, without
infections or cerebrovascular disease [4-6]. Of note, our pa-
tient fulfilled all the criteria for the mild phenotype of SIOD,
i.e., absence of disease symptoms in the 1st year of life [1],
growth failure and nephrotic syndrome starting in child-
hood [2], normal thyroid function tests and [5] no infectious
or cerebrovascular symptoms until now [4,5]. However early
recognition of characteristic growth retardation coupled
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diagnosis of this genetic disease even in mild form. Skeletal
examination in these patients may show bone changes sug-
gestive for spondyloepiphyseal dysplasia, driving the correct
diagnosis.
Usually, patients with SMARCAL1 biallelic missense
mutations or a missense and a nonsense mutation have a
milder disease. Accordingly, our patient, compound het-
erozygous for a novel missense mutation (p.Arg247Pro)
and a well-known nonsense mutation (p.Glu848*) [9], dis-
played a mild form. The missense mutation (p.Arg247Pro)
within the first HARP domain (HARP1), described for the
first time in this report, is located in a highest-conserved
site of the multi-sequence alignment (Figure 2B) and is
predicted to be a damaging change by SIFT (Sorting In-
tolerant From Tolerant) programme [13] with a score of
0.0 and a ‘probably damaging’ substitution by Polyphen-
programme [14] with a score of 1.000. All SNF2 proteins
are characterized by the presence of SWI/SNF helicase
motifs but do not always exhibit helicase activity. SMAR-
CAL1 protein has ATP-dependent annealing helicase ac-
tivity, which helps to stabilize stalled replication forks and
facilitate DNA repair during replication. Recently, it was
shown that the conserved tandem HARP (2HP) domain
dictates this annealing helicase activity, suggesting that the
HARP domains are important determinants of the SMAR-
CAL1 enzyme specificity [17]. The nonsense mutation, p.
Glu848*, leading to a truncated SMARCAL1 protein of
847 aa, was previously reported in other SIOD patients
with different ethnic origin [9].
The patient was referred to our attention because of onset
of proteinuria in nephrotic range. Renal biopsy revealed
FSGS, which is the most frequent renal pathological finding
associated with SIOD, as described in a revision of 39 SIOD
cases with proteinuria [18]. Nevertheless cases of minimal
change disease, membranous nephropathy, mesangial prolif-
erative glomerulonephritis and nephrophthisis have been
also described [15,18]. Kidney involvement in SIOD patients
displays typically proteinuria evolving to overt nephrotic
syndrome, usually diagnosed between 1–14 years [4-6,9].
This genetic form of nephrotic syndrome usually does not
respond to steroid treatment [6,16]; nevertheless, transient
reductions in proteinuria using ACE-inhibitors, NSAID or
even cyclosporine-A have been documented [4-6,9]. Our ex-
perience demonstrate that nephrotic proteinuria associated
with a mild form of SIOD may respond to combined ther-
apy with ACE- inhibitors and sartans, supporting the con-
cept that several missense mutations in SMARCAL1 gene
retain some residual function [15]. However most of pa-
tients, mainly with severe forms, progress to ESRD between
5–15 years of age. No relapse of proteinuria has been de-
scribed in SIOD patients after renal transplantation [15],
while the evolution of cerebrovascular and infectious com-
plications do not seem to improve after transplantation.In conclusion, we report a mild phenotypic expression
of SIOD associated with a new genotype consisting of
compound-heterozygosity for a known nonsense mutation
and a novel SMARCAL1 missense change, characterized
by nephrotic proteinuria, which decreased after combined
therapy with ACE inhibitors and sartans. Our experience
highlighted the importance of detailed clinical evaluation,
appropriate genetic counseling and molecular testing, to
provide timely treatment and more accurate prognosis.
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